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ABSTRACT
Objectives The diagnosis of repeat syphilis and its follow- 
up remains challenging. We aimed to investigate if IgM 
testing may assist in the diagnosis of syphilis reinfection/
relapse and its treatment follow- up.
Methods This substudy was conducted in the context 
of a syphilis biomarker discovery study ( ClinicalTrials. 
gov Nr: NCT02059525). Sera were collected from 120 
individuals with a new diagnosis of syphilis (72 with repeat 
infections) and 30 syphilis negative controls during a 
cohort study investigating syphilis biomarkers conducted 
at a sexually transmitted infection/HIV clinic in Antwerp, 
Belgium. Syphilis was diagnosed based on a simultaneous 
positive treponemal and non- treponemal assay result and/
or positive serum PCR targeting polA. Specimens collected 
at visit of diagnosis, and 3 and 6 months post- treatment 
were tested by two enzyme immunoassays (EIAs), 
recomWell (Mikrogen; MI) and Euroimmun (EU), to detect 
anti- treponemal IgM. Baseline specimens were also tested 
for anti- treponemal IgM using a line immunoassay (LIA) 
recomLine (MI). Quantitative kinetic decay curves were 
constructed from the longitudinal quantitative EIA results.
Results An overall sensitivity for the diagnosis of syphilis 
of 59.8% (95% CI: 50.3%–68.7%), 75.0% (95% CI: 
66.1%–82.3%) and 63.3% (95% CI: 54.8%–72.6%) was 
obtained for the EU, MI EIAs and MI LIA, respectively. When 
only considering repeat syphilis, the diagnostic sensitivity 
decreased to 45.7% (95% CI: 33.9%–58.0%), 63.9% (95% 
CI: 51.7%–74.6%) and 47.2% (95% CI: 35.5%–59.3%), 
respectively. IgM seroreverted in most cases 6 months 
after treatment. Post- treatment IgM concentrations 
decreased almost 30% faster for initial syphilis compared 
with repeat infection. The IgM EIAs and IgM LIA agreed 
from fairly to moderately (Cohen’s kappa (κ): 0.36 (EU EIA); 
κ: 0.53 (MI EIA); κ: 0.40 (MI LIA)) with the diagnosis of 
syphilis.
Conclusions IgM detection was not a sensitive method to 
diagnose syphilis and was even poorer in the diagnosis of 
syphilis repeat infections.
INTRODUCTION
Syphilis has re- emerged during the last 15 
years as a major public health problem with 
increasing incidence particularly among 
men who have sex with men (MSM) in the 
northern hemisphere.1 It is a multistage 
chronic disease caused by Treponema pallidum 
subspecies pallidum, and can be challenging 
to diagnose, especially very early and repeat 
infections. Diagnostic strategies remain 
reliant on serological testing, however, defi-
ciencies in assay performance and persistent 
anti- treponemal antibody presence following 
initial infection often hamper diagnostic 
accuracy.2
As the epidemics progress, an increasing 
proportion of all infections have been noted 
to be reinfections.3 Since reinfections are 
more likely to present asymptomatically,4 5 
timely diagnosis depends on the diagnostic 
accuracy of serological tests.
Since treponemal tests (TT) remain posi-
tive for life, the diagnosis of reinfections typi-
cally depends on fourfold or greater rises in 
non- treponemal test (NTT) titres, such as the 
rapid plasma reagin (RPR) test. Conversely, 
a fourfold decline in NTT titres is used to 
determine the success of syphilis treatment. 
Strengths and limitations of this study
 ► The clinical utility of IgM detection was investigat-
ed for the diagnosis of syphilis and post- treatment 
follow- up in a prospective cohort of 120 individuals 
with a new episode of syphilis (72 with repeat infec-
tions) and 30 syphilis negative controls.
 ► Syphilis was diagnosed based on a simultaneous 
positive treponemal and non- treponemal assay re-
sult and/or positive serum PCR targeting polA.
 ► Sera collected at visit of diagnosis, and 3 and 6 
months post- treatment were tested by two differ-
ent commercially available enzyme immunoassays 
to detect anti- treponemal IgM, whereby quantitative 
kinetic decay curves were constructed from the lon-
gitudinal quantitative results.
 ► Specimens collected at diagnosis were also tested 
for anti- treponemal IgM using a line immunoassay.
 ► The study population was mostly HIV- infected men 
who have sex with men taking antiretroviral therapy, 
therefore the possible effects of HIV infection such 
as viral load and CD4+ T cell count and gender were 
not controlled for.
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Due to the aspecific nature of NTTs, that relies on anti-
body binding to lipoidal components released during 
host cell destruction and also present in low quantities 
in the T. pallidum cell wall,6 other biological, infectious 
or immunological mechanisms can also result in fluctua-
tions in NTT leading to false positive results.7
Following an initial infection, immunoglobulin (Ig)M 
antibodies are the first class of antibodies produced. Early 
detection of IgM could therefore help with the diagnosis 
of early syphilis. Current European syphilis guidelines8 
mention that IgM testing is useful in the assessment of 
newborns and cerebral spinal fluid. These guidelines also 
note that a negative IgM result cannot exclude the diag-
nosis of congenital or neurosyphilis. There is however 
little published on the clinical utility of IgM testing in 
these contexts. A study published in 20139 evaluated 
three commercially available IgM enzyme immunoas-
says (EIAs) using 307 serum samples from individuals 
with active syphilis. It found that these IgM assays had a 
median sensitivity of 84.5% with specificities in the range 
of 91.4%–100%. In 23/59 (39%) of cases the IgM EIA 
test was positive in suspected very early infection where 
the NTT was negative. Even less has been published in 
the context of the current outbreaks of syphilis. In many 
countries a large proportion, and sometimes most syphilis 
cases, are repeat episodes of syphilis.4 5 IgM responses are 
frequently different in repeat episodes of infection.9 10 We 
could only find one paper that has evaluated the utility of 
IgM testing for the diagnosis of repeat syphilis. This was 
a prospective analysis of IgM among a cohort of MSM. It 
found a low performance of the EIA IgM test for repeat 
syphilis diagnosis, namely only 38.5% of repeat syphilis 
cases were diagnosed correctly with IgM testing.11 The 
number of patients with repeat syphilis in the study was 
only 13.
In this study we investigated the clinical utility of IgM 
detection in the diagnosis of syphilis and post- treatment 
follow- up in a prospective cohort of 120 individuals with 
a new episode of syphilis. In addition, we evaluated the 
performance of three commercially that is, two EIAs and 
one line immuno assay (LIA), IgM assays.
MATERIALS AND METHODS
Study design
Potentially eligible study participants 18 years or older, 
in whom a new syphilis diagnosis was made, were consec-
utively screened and prospectively recruited between 
January 2014 and August 2015 at a sexually transmitted 
infection (STI)/HIV clinic in Antwerp, Belgium. Study 
exclusion criteria were the use of beta- lactam, doxy-
cycline or macrolide antibiotics during the 28 days 
preceding enrolment. Syphilis diagnosis and disease 
staging were performed by the study physician according 
to the Centers for Disease Control guidelines.12 Reinfec-
tion was defined as an episode of syphilis that followed 
a previously clearly documented episode of syphilis.3 13 
Stage- appropriate treatment was administered according 
to European guidelines.13 This involved intramuscular 
benzathine penicillin 2.4 mu weekly for 3 weeks for late 
latent syphilis and a stat dose for primary, secondary and 
early latent syphilis. All participants with syphilis were 
followed- up by the study team at the STI clinic 3 and 
6 months post- treatment. The study physician recorded 
clinical details and laboratory results in a standardised 
fashion during each study visit. HIV- infected controls with 
both negative NTT and TT results were included during 
the same recruitment period at the same study location. 
Clinical details were recorded for the controls during a 
single clinical visit, followed by a same day blood draw.
Patient and public involvement
Patients or the public were not involved in the design of 
the study.
Clinical serological testing during routine workout
Blood was drawn into serum gel tubes (Sarstedt Monovette, 
Nümbrecht, Germany). Sera were divided and either (1) 
stored at 4°C–8°C until routine syphilis serological testing 
within 4 days or (2) stored at −80°C within 3 hours for later 
testing. Routine serological testing included Macro- Vue 
RPR Card (Becton Dickinson, Sparks, Maryland, USA) 
and TPA assay (Ortho- Clinical Diagnostics, Rochester, 
New York, USA) testing following the manufacturer’s 
instructions. Positive RPR results were determined to a 
titre endpoint.
Sera obtained at baseline were also tested with the 
SERODIA-T. pallidum particle agglutination (TP- PA) 
(Fujirebio, Tokyo, Japan) assay and an in- house T. pall-
idum PCR targeting polA.14
EIA and LIA testing for IgM serum antibodies
In order to investigate if assays from different manufac-
turers or using another method performed differently 
and thus would have an impact on our study outcome, we 
evaluated side by side two IgM EIAs and one LIA.
The anti-T. pallidum IgM EIAs were provided by Euro-
immun (Lübeck, Germany) and by Mikrogen GmbH 
(Neuried, Germany), henceforth referred to as ‘EU EIA’ 
and ‘MI EIA’, respectively. Both assays use microplate 
wells coated with a mixture of four antigens of T. pallidum: 
Tp15, Tp17, Tp47 and TmpA. Testing was performed 
following the manufacturer’s instructions ( EI_ 2111M_ 
A_ UK_ C07. doc; V.08/09/2011 and  GIRETP011DE. doc; 
V.April 2010). All quantitative EIA results were expressed 
in International Units (IU)/mL. The lower detection limit 
of the EU EIA was defined as the ratio value of 0.06 by the 
manufacturer. A ratio result of ≥0.8 to <1.1 was defined as 
borderline. The results were semi- quantitatively evaluated 
by calculating a ratio of the extinction value of the patient 
sample over the extinction value of the calibrators. The 
manufacturer reported a sensitivity and specificity of 
100%, with an intra- assay variation (CV) of 4.17% and 
inter- assay CV of 5.3%. With regards to the MI EIA, the 
manufacturer reported sensitivity was 100%, intra- assay 
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CV 4.5% and inter- assay CV <11%. Borderline values were 
defined as ≥20–≤24 IU/mL.
The recomLine Treponema LIA kit (MI LIA) (Mikrogen 
GmbH) was used for the qualitative determination of 
the IgM antibodies for baseline samples. This test uses 
recombinant T. pallidum antigens fixed on nitrocellu-
lose membrane strips. Testing was performed according 
to the manufacturer’s instructions (GARLTP002EN, 
V.2012/08). Objective reading of the strips was done 
by scanning the strips with a flatbed scanner and anal-
ysis software Recomscan (Mikrogen). The density of the 
antigen was compared with a positive control and ratios 
were calculated. The assay was reported negative if no 
antigen was detected (ratio <1), borderline if only one 
random antigen was detected (ratio ≥1) and positive if at 
least two random antigens were present (ratio ≥1). The 
manufacturer reported sensitivity was 100% and speci-
ficity 95%.
Quality control
The samples were analysed by a research and diagnostic 
laboratory unit, both are ISO15189 accredited. One single 
lot number was used for all EIAs and LIAs. Two labora-
tory technicians performed the analyses during two batch 
testing periods of 14 days in 2016. Evaluative testing of 
the EIAs took place maximum 974 days after the samples 
of interest were collected. Samples were thawed, tested 
and refrozen on the same day with a maximum of two 
freeze thaw cycles.
Due to the prolonged testing period and nature of the 
routine diagnostic laboratory setting, the reagents used 
for the TPPA, TPA and RPR tests were from different lot 
numbers.
The laboratory technicians were blinded from the 
patient’s clinical information and any other syphilis 
serology result.
Data were manually double entered into the database.
Definitions
In the absence of a single gold standard test for syphilis, 
a positive RPR test, or in the case of reinfection a four-
fold increase in RPR titre, together with a positive TPPA/
TPA results or a positive T. pallidum PCR test were used to 
define a new syphilis episode (‘syphilis diagnosis’).
Statistical analysis
Percentage agreement and Cohen’s kappa (κ)- coefficient 
value15 were calculated to estimate agreement between 
the IgM test results. The sensitivity, specificity, positive 
and negative predictive values with 95% CIs were calcu-
lated using the baseline visit samples. Borderline results 
for the EIA and LIA testing were included for the first set 
of analyses as negative (specific scenario) and the second 
dataset included all borderline results as positive (sensi-
tive scenario).
Continuous variables were expressed as median values 
and IQR. Associations between categorical variables 
were assessed with the χ2 test and Fisher’s exact test for 
small numbers. Mann- Whitney U test was performed 
to compare the quantitative results of the IgM assays 
between initial and repeat syphilis groups, in addition to 
symptomatic (primary and secondary stage) versus latent 
syphilis groups. An all- available case approach was used 
throughout all analyses. Analyses were performed in Stata 
V.13.1 (StataCorp, College Station, Texas, USA). The 
statistical significance level was set at 0.05.
Non- linear models were used to visually assess the decay 
of the IgM concentrations and RPR titres over time. The 
exponential decay curves were of the form Y=a*e- b*X, 
where Y was the measurement of the EIA tests and X the 
time in months. The exponential decay curves and the 
graphics were designed using R V.3.4.416 and the package 
nlstools.17
RESULTS
Study participants
In total 150 individuals were included in the study, 120 
diagnosed with syphilis and 30 controls.18 Study subject 
characteristics are described in table 1. Of those who 
had active syphilis at the time of study enrolment 48/120 
Table 1 Study subject characteristics
Characteristics
Syphilis- positive 
cases
(N=120)
Controls*
(N=30)
n (%)/median 
(IQR)
n (%)/median 
(IQR)
Gender (male) 119 (99) 30 (100)
MSM 117 (98) 24 (80)†
HIV- infected 103 (86) 30 (100)†
Taking ART 91 (88) 24 (80)
Benzathine penicillin 
G treatment
117 (98) NA
RPR- C titre at 
baseline
64 (32–128) 0
Age (years) 40 (31.5–48) 37.5 (32–45)
CD4+ T cell count 598 (448–749) 577 (392–684)
Syphilis stages and infection history
Syphilis stage Initial infection‡ Repeat 
infection‡
Primary 12 (10) 11 (9)
Secondary 22 (18) 28 (23)
Early latent 7 (6) 24 (20)
Late latent 7 (6) 9 (8)
*Control subjects were all HIV positive and non- treponemal and 
treponemal antibody negative at the time of study inclusion.
†Statistically significant difference between syphilis positive group 
and controls.
‡Percentage calculated with denominator n=120 syphilis- positive 
subject.
ART, antiretroviral therapy; MSM, men who have sex with men; NA, 
not applicable; RPR, rapid plasma reagin.
4300.7802.430. Protected by copyright.
 o
n
 O
ctober 9, 2020 at Erasm
us M
edical / X51
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-035838 on 21 September 2020. Downloaded from 
4 Osbak KK, et al. BMJ Open 2020;10:e035838. doi:10.1136/bmjopen-2019-035838
Open access 
(40%) presented with a first episode of syphilis (hence-
forth referred to as ‘initial infection’) and 72/120 (60%) 
presented with a repeat infection. Previous NTT results 
were available for 107/120, the remaining 13 individuals 
without previous serological test results were classified as 
having an initial infection based on the fact that they had 
never had a diagnosis of or symptoms suggestive of syph-
ilis before. Although initial infections were more often 
symptomatic 34/48 (71%) compared with the repeat 
infections 39/72 (54%), this difference did not reach 
statistical significance (p=0.09).5
IgM test results
The IgM testing was performed on 339, 343 and 150 sera 
by the EU, MI EIAs and LIA, respectively. Details of the 
qualitative results are presented in table 2. One sample 
from a control patient tested IgM positive and another 
one tested borderline positive with the MI EIA. The LIA 
also had one false positive and one borderline result. All 
control samples tested negative with the EU EIA. Slight 
differences in the number of samples tested per visit 
(baseline N=3 and M6 N=1) between the two EIAs was 
due to logistical error. Samples were not available for all 
follow- up visits due to non- attendance; the reason was not 
recorded.
IgM test performs sub-optimally for diagnosis of syphilis
The overall diagnostic performance for the two IgM 
EIAs and LIA assays evaluated was moderate. Table 3 
summarises the assay performances in the specific- case 
scenario. The diagnostic sensitivities of the evaluated 
assays ranged from 80.9% to 91.7% when applied to 
samples collected at baseline from individuals with initial 
syphilis. When baseline analyses were stratified per initial 
or repeat infection, the diagnostic sensitivity decreased 
significantly in repeat infections for all assays evaluated 
compared with initial infection (p=0.002 (MI EIA); 
p=0.003 (EU EIA); p<0.0001 (LIA MI)).
The performances of the assay in the sensitive- case 
scenario are presented in online supplemental table S1.
LIA IgM testing of baseline samples
The overall performance of the LIA test was moderate 
(tables 2 and 3). Of the six antigen lines evaluated, 
Tp47 and TmpA were the most frequently positive. No 
samples were positive for the marker Tp257. A heat map 
was created comparing the RPR titre and MI LIA (online 
supplemental figure S2).
Quantitative assessment of baseline samples with EIA
When considering the quantitative results of the two EIAs, 
a significant difference was found between the initial and 
repeat syphilis groups (EU p=0.0000; MI p=0.0002) with 
repeat syphilis having lower IgM concentrations. More-
over, the concentrations were significantly lower for indi-
viduals presenting with latent stage syphilis compared 
with primary and secondary stage (EU EIA p=0.001; MI 
EIA p=0.0002).
Longitudinal post-treatment follow-up at 3 months and 6 
months and kinetic decay curve characteristics of EIA testing
At 6 months post- treatment seroreversion of IgM test 
results occurred in 57/70 (81%) samples tested by the 
EU EIA and 66/90 (73%) tested by MI EIA. Among 
the month 6 samples for which a seroreversion was not 
observed, 6/13 and 7/24 tested with the EU EIA and MI 
EIA, respectively, did not show a decrease in RPR titre 
either. Overall, in a total of 19 individuals a decrease 
in RPR titre post- treatment was not observed. Individ-
uals with an initial syphilis infection demonstrated a 
faster decrease of almost 30% in analyte concentration 
for every additional time unit (0.55 (95% CI: 0.36–
0.68)) compared with a repeat syphilis (0.74 (95% CI: 
0.62–0.83)) (figure 1). Online supplemental figure S3 
represents the decay curves of IgM EIA MI concentration 
and RPR titres over time.
Agreement between the commercial IgM tests
The overall agreement was substantial between the two 
EIA tests when considering all samples that is, samples 
from baseline, M3 and M6, tested by both assays (N=339). 
The Cohen’s kappa was κ: 0.69 (85.3%) and κ: 0.74 
(86.7%) for the specific- case and sensitive- case scenarios, 
respectively.
There was a strong agreement between the LIA and the 
EIAs: 90.7% (κ: 0.81) between the MI EIA and MI LIA, 
and 95.3% (κ: 0.91) between EU EIA and MI LIA in the 
specific- case scenario. In the sensitive- case scenario the 
agreement between MI EIA and MI LIA increased further 
up to 99.3% (κ: 0.91) but decreased between EU EIA and 
MI LIA to 88.7% (κ: 0.77).
DISCUSSION
We aimed to determine whether testing for IgM could 
aid in the diagnosis of new syphilis infections, including 
repeat infections, and if it could be useful for post- 
treatment follow- up. Detection of IgM may help in 
the diagnosis of syphilis but its diagnostic sensitivity is 
poor, it was notably low in participants diagnosed with 
repeat syphilis. Our results are, however, congruent with 
previous reports of suboptimal IgM test performance 
overall and for repeat syphilis in particular.11 The lower 
diagnostic sensitivity of IgM in repeat syphilis is compat-
ible with results from other infections where reinfections 
lead directly to increases in IgG without initial increases 
in IgM.10
This study represents the most comprehensive evalu-
ation of EIA and LIA IgM testing on serum from indi-
viduals with syphilis that we are aware of. We found that 
both EIA agreed substantially, although that the MI EIA 
performed in terms of diagnostic sensitivity better than 
the EU assay. The difference between both sandwich 
EIAs lays in the pre- treatment of serum with the IgG/
rheumatoid factor (RF) absorbant included in the EIA 
reagent kit of EU. The absorbant removes the antibodies 
of the IgG classes and the RFs, known to be possible 
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interferences in IgM EIA. False positive reactions may 
occur in pathogen- specific IgM detection when the IgM 
RFs bind to IgG immune complexes. On the other hand, 
false negative results may appear when pathogen- specific 
IgM antibodies are displaced by stronger binding IgG.19 
We cannot rule out that this extra IgG/RF removal step 
may have contributed to the differences in test perfor-
mance found between both EIAs.
The general performance of the LIA for the baseline 
syphilis diagnosis was similar to the EIAs. The antigen 
line reaction varied by sample and in some samples only 
a few antigens could be demonstrated. Since no partic-
ular single antigen or line can be attributed to a stage or 
profile, an overall qualitative result should be considered.
In the majority of the IgM positive cases detected at 
baseline, the IgM antibodies disappeared 6 months after 
Table 3 Cross- tabulations and performance characteristics of the serological assays (EIAs/LIA) tested in this study according 
to the specific scenario*
Syphilis IgM positive IgM negative Total Characteristics % (95% CI)
MI EIA all baseline samples
  Positive 90 30 120 Sensitivity: 75.0 (66.1–82.3)
Specificity: 96.7 (80.9–99.8)
PPV: 98.9 (93.2–99.9)
NPV: 40.2 (37.6–63.9)
  Negative 1 29 30
  Total 91 59 150
MI initial infection baseline only
  Positive 44 4 48 Sensitivity: 91.7 (79.1–97.3)
Specificity: 96.7 (80.9–99.8)
PPV: 97.8 (86.8–99.9)
NPV: 87.9 (70.9–96.0)
  Negative 1 29 30
  Total 45 33 78
MI repeat infection baseline only
  Positive 46 26 72 Sensitivity: 63.9 (51.7–74.6)
Specificity: 96.7 (80.9–99.8)
PPV: 97.8 (87.3–99.9)
NPV: 52.7 (38.9–66.1)
  Negative 1 29 30
  Total 47 55 102
EU EIA all baseline samples
  Positive 70 47 117 Sensitivity: 59.8 (50.3–68.7)
Specificity: 100 (85.9–100)
PPV: 100 (93.5–100)
NPV: 38.9 (28.3–50.8)
  Negative 0 30 30
  Total 70 77 147
EU initial infections baseline only
  Positive 38 9 47 Sensitivity: 80.9 (66.3–90.4)
Specificity: 100 (85.9–100)
PPV: 100 (88.6–100)
NPV: 76.9 (60.3–88.3)
  Negative 0 30 30
  Total 38 39 77
EU repeat infections baseline only
  Positive 32 38 70 Sensitivity: 45.7 (33.9–58.0)
Specificity: 100 (85.9–100)
PPV: 100 (86.7–100)
NPV: 44.1 (32.3–56.6)
  Negative 0 30 30
  Total 32 68 100
LIA all baseline samples
  Positive 76 44 120 Sensitivity: 63.3 (54.0–71.8)
Specificity: 96.7 (80.9–99.8)
PPV: 98.7 (92.0–99.9)
NPV: 39.7 (28.7–51.9)
  Negative 1 29 30
  Total 78 72 150
LIA initial Infections baseline only
  Positive 42 6 48 Sensitivity: 87.5 (74.1–94.8)
Specificity: 96.7 (80.9–99.8)
PPV: 97.7 86.2–99.9)
NPV: 82.9 (65.7–92.8)
  Negative 1 29 30
  Total 43 35 78
LIA repeat Infections at baseline only
  Positive 34 38 72 Sensitivity: 47.2 (35.5–59.3)
Specificity: 96.7 (80.9–99.8)
PPV: 97.1 (83.4–99.9)
NPV: 43.3 (31.4–55.9)
  Negative 1 29 30
  Total 35 67 102
* Borderline results included as negative for all values.
EIA, enzyme immunoassay; EU, Euroimmun; LIA, line immunoassay; MI, Mikrogen; NPV, negative predictive value; ; PPV, positive predictive value.
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treatment. Interestingly, the decline in IgM concentra-
tions occurred faster in initial syphilis compared with 
repeat syphilis. Our study hints but remains inconclusive 
and additional studies are required to investigate whether 
IgM concentration measurements may be a more objec-
tive, useful and high throughput method compared with 
RPR for the follow- up of syphilis treatment.
More studies are needed to investigate the role of IgM 
in syphilis diagnosis on a more diversified and larger scale 
(eg, women, non- MSM populations). Since our study only 
included individuals with a dual positive NTT/TT we were 
unable to evaluate if IgM values might precede NTT/TT 
seroconversion. A previous study did find that IgM could 
be useful in the early diagnosis of syphilis in the subset of 
patients with equivocal TT and negative NTTs.9
Strengths of this study include the comprehensive char-
acterisation of sera and its prospective nature. Limitations 
to this study include the fact that the study population 
was mostly HIV infected. We did not control for possible 
effects of HIV infection such as viral load and CD4+ T cell 
count, although notably most HIV- infected participants 
were taking antiretroviral therapy and had a high immune 
cell count thus the likelihood of this having an effect on 
the test outcome is unlikely. The study was not designed 
to adequately evaluate the assays’ specificity.20 Previous 
serology results were not available for 13 patients. For 
this group syphilis history was reliant on patient recall 
of clinical symptoms. It is possible that some individ-
uals unknowingly had a previous syphilis episode, there-
fore the number of reinfections could be higher than 
reported. This could possibly affect IgM performance 
results. Moreover, follow- up sera samples were not avail-
able for all 3M and 6M study participants, however, most 
(88%) endpoint M6 samples were analysed.
CONCLUSIONS
In conclusion, the overall diagnostic performance for 
the two IgM EIAs and LIA assays evaluated was moderate. 
When IgM results were stratified per initial or repeat 
infection, the diagnostic sensitivity decreased signifi-
cantly in repeat infections for all assays evaluated. This 
could lead to missed infections. Individuals with repeat 
syphilis or presenting with latent stage syphilis had lower 
IgM concentrations compared with initial infection and 
primary/secondary stage syphilis, respectively. Future 
research could evaluate the utility of IgM in the follow- up 
of treatment. For example, serial IgM testing may play a 
role in the management of serofast syphilis.
Figure 1 Initial and post- treatment decay curves of recomWell EIA IgM. EIA, enzyme immunoassay.
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